Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Paclitaxel + ifosfamide + cisplatin, commonly referred to as the TIP regimen, is a combination chemotherapy protocol primarily used for the treatment of testicular germ cell tumors (GCTs), especially in cases where the disease has relapsed or is refractory to first-line therapy. It is also studied in other cancers such as advanced or recurrent cervical cancer. Paclitaxel acts by stabilizing microtubules and inhibiting their disassembly, thereby blocking cell division. Ifosfamide is an alkylating agent that cross-links DNA strands, leading to apoptosis. Cisplatin forms DNA crosslinks and inhibits DNA synthesis and function, resulting in cell death. The combination exploits different mechanisms of action to maximize cytotoxicity against rapidly dividing tumor cells[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on paclitaxel + ifosfamide + cisplatin.